These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24657510)

  • 1. Efficacy and safety of prasugrel in acute coronary syndrome patients.
    Nanau RM; Delzor F; Neuman MG
    Clin Biochem; 2014 May; 47(7-8):516-28. PubMed ID: 24657510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will prasugrel supersede clopidogrel for acute coronary syndromes?
    Hankey GJ; Eikelboom JW; Langton PE
    Med J Aust; 2008 Apr; 188(7):381-2. PubMed ID: 18393737
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.
    Rodriguez L; Conde D; Lalor N; Elissamburu P; Trivi M
    Am J Emerg Med; 2013 Aug; 31(8):1287. PubMed ID: 23769852
    [No Abstract]   [Full Text] [Related]  

  • 4. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel versus prasugrel: times are changing, but not for everyone.
    Dobesh PP
    Pharmacotherapy; 2009 Dec; 29(12):1393-6. PubMed ID: 19947798
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
    O'Donoghue ML; Braunwald E; Antman EM; Murphy SA; Bates ER; Rozenman Y; Michelson AD; Hautvast RW; Ver Lee PN; Close SL; Shen L; Mega JL; Sabatine MS; Wiviott SD
    Lancet; 2009 Sep; 374(9694):989-997. PubMed ID: 19726078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. For better or for worse: the future of antiplatelet therapy.
    Alvarez W
    Am J Health Syst Pharm; 2008 Jun; 65(11):1017. PubMed ID: 18499873
    [No Abstract]   [Full Text] [Related]  

  • 8. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
    Lazar LD; Lincoff AM
    Cleve Clin J Med; 2009 Dec; 76(12):707-14. PubMed ID: 19952295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel: Clinical development and therapeutic application.
    Guerra DR; Tcheng JE
    Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prasugrel: a novel antiplatelet agent.
    Riley AB; Tafreshi MJ; Haber SL
    Am J Health Syst Pharm; 2008 Jun; 65(11):1019-28. PubMed ID: 18499874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Platelet inhibition with prasugrel].
    Gassanov N; Caglayan E; Nia AM; Erdmann E; Er F
    Dtsch Med Wochenschr; 2010 Aug; 135(31-32):1542-6. PubMed ID: 20665417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
    Salisbury AC; Wang K; Cohen DJ; Li Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):27-34. PubMed ID: 23212457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
    Martin MT; Spinler SA; Nutescu EA
    Clin Ther; 2011 Apr; 33(4):425-42. PubMed ID: 21635989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
    Tcheng JE; Mackay SM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):83-91. PubMed ID: 22316323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel.
    Lalor N; Conde D; Rodriguez L; Elissamburu P; Trivi M
    Am J Emerg Med; 2013 Aug; 31(8):1287-8. PubMed ID: 23806726
    [No Abstract]   [Full Text] [Related]  

  • 17. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
    Mariani M; Mariani G; De Servi S
    Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel versus clopidogrel.
    Serebruany V
    N Engl J Med; 2008 Mar; 358(12):1298; author reply 1299-301. PubMed ID: 18354110
    [No Abstract]   [Full Text] [Related]  

  • 20. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
    Greenhalgh J; Bagust A; Boland A; Saborido CM; Fleeman N; McLeod C; Dundar Y; Dickson R; Proudlove C; Kolamunnage-Dona R; Fisher M
    Health Technol Assess; 2010 May; 14 Suppl 1():31-8. PubMed ID: 20507801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.